These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
530 related articles for article (PubMed ID: 24699304)
21. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Fiskus W; Sharma S; Saha S; Shah B; Devaraj SG; Sun B; Horrigan S; Leveque C; Zu Y; Iyer S; Bhalla KN Leukemia; 2015 Jun; 29(6):1267-78. PubMed ID: 25482131 [TBL] [Abstract][Full Text] [Related]
22. Identification of JL1037 as a novel, specific, reversible lysine-specific demethylase 1 inhibitor that induce apoptosis and autophagy of AML cells. Liu S; Lu W; Li S; Li S; Liu J; Xing Y; Zhang S; Zhou JZ; Xing H; Xu Y; Rao Q; Deng C; Wang M; Wang J Oncotarget; 2017 May; 8(19):31901-31914. PubMed ID: 28404874 [TBL] [Abstract][Full Text] [Related]
23. SP2509, a Selective Inhibitor of LSD1, Suppresses Retinoblastoma Growth by Downregulating β-catenin Signaling. Jiang A; Wu W; Xu C; Mao L; Ao S; Guo H; Sun X; Tao J; Sang Y; Huang G Invest Ophthalmol Vis Sci; 2022 Mar; 63(3):20. PubMed ID: 35297943 [TBL] [Abstract][Full Text] [Related]
24. Crystal Structure of the LSD1/CoREST Histone Demethylase Bound to Its Nucleosome Substrate. Kim SA; Zhu J; Yennawar N; Eek P; Tan S Mol Cell; 2020 Jun; 78(5):903-914.e4. PubMed ID: 32396821 [TBL] [Abstract][Full Text] [Related]
25. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia. Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW Gene; 2020 Aug; 752():144758. PubMed ID: 32422235 [TBL] [Abstract][Full Text] [Related]
26. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia. Przespolewski A; Wang ES Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938 [TBL] [Abstract][Full Text] [Related]
27. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia. Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629 [TBL] [Abstract][Full Text] [Related]
28. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer. Hosseini A; Minucci S Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367 [TBL] [Abstract][Full Text] [Related]
29. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells. Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255 [TBL] [Abstract][Full Text] [Related]
30. Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines. Welch D; Kahen E; Fridley B; Brohl AS; Cubitt CL; Reed DR PLoS One; 2019; 14(9):e0222228. PubMed ID: 31550266 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia. Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337 [TBL] [Abstract][Full Text] [Related]
32. Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer. Tan AHY; Tu W; McCuaig R; Hardy K; Donovan T; Tsimbalyuk S; Forwood JK; Rao S Front Immunol; 2019; 10():1351. PubMed ID: 31249575 [TBL] [Abstract][Full Text] [Related]
33. Intermolecular insights into allosteric inhibition of histone lysine-specific demethylase 1. Zhang X; Sun Y; Zhang Z; Wang H; Wang J; Zhao D Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129990. PubMed ID: 34390793 [TBL] [Abstract][Full Text] [Related]
34. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291 [TBL] [Abstract][Full Text] [Related]
35. CRISPR-suppressor scanning reveals a nonenzymatic role of LSD1 in AML. Vinyard ME; Su C; Siegenfeld AP; Waterbury AL; Freedy AM; Gosavi PM; Park Y; Kwan EE; Senzer BD; Doench JG; Bauer DE; Pinello L; Liau BB Nat Chem Biol; 2019 May; 15(5):529-539. PubMed ID: 30992567 [TBL] [Abstract][Full Text] [Related]
36. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293 [TBL] [Abstract][Full Text] [Related]